Clinical trial
Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients
NCT01657955 is registered in ClinicalTrials.gov with Shandong Lanjin Pharmaceuticals Co.,Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Study of Bendamustine Hydrochloride Injection in Previously Untreated Chronic Lymphocytic Leukemia Patients
- Lead sponsor
- Shandong Lanjin Pharmaceuticals Co.,Ltd
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- January 31, 2011
- Completion date
- December 31, 2013
- Enrollment
- 96 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.